As of 19 September 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of pneumococcal vaccines for the prevention of disease caused by Streptococcus pneumoniae in elderly adults 60 years old and above, including the following vaccine regimen: (1) pneumococcal conjugate vaccine 13 (PCV13) in sequence to pneumococcal polysaccharide continue reading : HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
As of 19 September 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of pneumococcal vaccines for the prevention of disease caused by Streptococcus pneumoniae in elderly adults 60 years old and above, including the following vaccine regimen: (1) pneumococcal conjugate vaccine 13 (PCV13) in sequence to pneumococcal polysaccharide continue reading : HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
HTAC Preliminary Recommendation for Government Financing of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease
Link to evidence summary Publication date: 07 September 2022 (Stakeholders may submit appeals to hta@doh.gov.ph until 22 September 2022 using the prescribe form found here: Topic Nomination ) Document Preview:
Preliminary Recommendation for the Non-Inclusion of Eribulin in the Treatment of Soft Tissue Sarcoma in the PNF
Document link: Evidence Summary (Proponents may submit appeals to hta@doh.gov.ph until 28 June 2022 using the prescribed form accessible via Topic Nomination.)